CA2471206A1 - Anticorps anticancereux personnalises - Google Patents

Anticorps anticancereux personnalises Download PDF

Info

Publication number
CA2471206A1
CA2471206A1 CA002471206A CA2471206A CA2471206A1 CA 2471206 A1 CA2471206 A1 CA 2471206A1 CA 002471206 A CA002471206 A CA 002471206A CA 2471206 A CA2471206 A CA 2471206A CA 2471206 A1 CA2471206 A1 CA 2471206A1
Authority
CA
Canada
Prior art keywords
antibodies
fragments
treating
cancerous
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002471206A
Other languages
English (en)
Inventor
David S. F. Young
Miyoko Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2471206A1 publication Critical patent/CA2471206A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode qui permet de produire des anticorps anticancéreux spécifiques du patient au moyen d'un nouveau modèle de criblage. La séparation des anticorps anticancéreux, qui utilise la cytotoxicité des cellules cancéreuses comme point final, permet de produire sur mesure des anticorps anticancéreux pour chaque patient à des fins thérapeutiques et diagnostiques.
CA002471206A 2001-12-21 2001-12-21 Anticorps anticancereux personnalises Abandoned CA2471206A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2001/001838 WO2003055515A1 (fr) 2001-12-21 2001-12-21 Anticorps anticancereux personnalises

Publications (1)

Publication Number Publication Date
CA2471206A1 true CA2471206A1 (fr) 2003-07-10

Family

ID=4143189

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002471206A Abandoned CA2471206A1 (fr) 2001-12-21 2001-12-21 Anticorps anticancereux personnalises

Country Status (5)

Country Link
EP (1) EP1455819A1 (fr)
JP (1) JP2005518393A (fr)
AU (1) AU2002226211A1 (fr)
CA (1) CA2471206A1 (fr)
WO (1) WO2003055515A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US7252821B2 (en) * 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) * 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
WO2004022580A2 (fr) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Peptides bh3 et leur methode d'utilisation
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7195764B2 (en) * 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
CA2692912A1 (fr) * 2007-07-16 2009-01-22 F. Hoffmann-La Roche Ag Anticorps modifiant une maladie cancereuse
CN101743256A (zh) * 2007-07-16 2010-06-16 霍夫曼-拉罗奇有限公司 抗癌细胞毒性单克隆抗体
WO2009009882A1 (fr) * 2007-07-16 2009-01-22 F. Hoffmann-La Roche Ag Anticorps modifiant une maladie cancéreuse
US20090068100A1 (en) * 2007-08-27 2009-03-12 Young David S F Cancerous disease modifying antibodies
US20090068099A1 (en) * 2007-09-10 2009-03-12 Young David S F Cancerous disease modifying antibodies
WO2009043166A1 (fr) * 2007-10-03 2009-04-09 F. Hoffmann-La Roche Ag Anticorps monoclonal cytotoxique anticancéreux
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191119A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191120A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
WO2009124381A1 (fr) * 2008-04-10 2009-10-15 F. Hoffmann-La Roche Ag Anticorps monoclonal cytotoxique anticancer
US20090304579A1 (en) * 2008-05-19 2009-12-10 Young David S F Cancerous Disease Modifying Antibodies
US20090304578A1 (en) * 2008-05-19 2009-12-10 Young David S F Cancerous Disease Modifying Antibodies
JP6352924B2 (ja) 2012-09-19 2018-07-04 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ダイナミックｂｈ３プロファイリング
CA2922503C (fr) 2013-09-19 2021-10-26 Dana-Farber Cancer Institute, Inc. Procede de profilage de bh3
JP6814745B2 (ja) 2015-04-27 2021-01-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1736495A (en) * 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies

Also Published As

Publication number Publication date
EP1455819A1 (fr) 2004-09-15
WO2003055515A1 (fr) 2003-07-10
AU2002226211A1 (en) 2003-07-15
JP2005518393A (ja) 2005-06-23

Similar Documents

Publication Publication Date Title
US7420039B2 (en) Individualized anti-cancer antibodies
US7247476B2 (en) Individualized anti-cancer antibodies
CA2471206A1 (fr) Anticorps anticancereux personnalises
JP2022088649A (ja) Ｍｕｃ１６に対する抗体およびその使用方法
AU2008235566B2 (en) Anti-EpCAM antibody and uses thereof
JP2007523834A (ja) 癌疾患修飾抗体
US7256271B2 (en) Cancerous disease modifying antibodies
AU2005217007A1 (en) Cancerous disease modifying antibodies
WO2003086456A2 (fr) Profilage antigenique de cellules neoplasiques, therapie oncogene faisant appel a des anticorps fonctionnels diriges contre lesdites cellules et complexes immuns cytotoxiques ainsi formes
EP1360208B1 (fr) Procede de production d'anticorps cytotoxiques anticancereux
AU2004205435A1 (en) Cancerous disease modifying antibodies
CA2521375A1 (fr) Anticorps ayant une action sur une maladie cancereuse
WO2005111198A1 (fr) Anticorps modifiant les maladies cancereuses
US20050027106A1 (en) Cancerous disease modifying antibodies
EP1757305A2 (fr) Anticorps anticancéreux personnalisés

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead